Report of Foreign Issuer (6-k)
September 25 2015 - 6:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2015
Commission File Number
Novogen
Limited
(Translation of registrants name into English)
16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No þ
If yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Novogen Limited (Registrant)
Lionel Mateo
Lionel Mateo
Company Secretary
Date 25 September 2015
Appendix 3Y
Change of Directors Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of
Directors Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents
given to ASX become ASXs property and may be made public.
Introduced 30/09/01 Amended 01/01/11
|
Name of entity Novogen Limited (Novogen) |
|
ABN 37 063 259 754 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes
of section 205G of the Corporations Act.
|
|
|
Name of Director |
|
Mr Iain Ross |
Date of last notice |
|
|
Part 1 - Change of directors relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of notifiable interest of a director should be
disclosed in this part.
|
|
|
Direct or indirect interest |
|
Direct |
|
|
Nature of indirect interest
(including registered holder) Note: Provide details of the
circumstances giving rise to the relevant interest. |
|
|
|
|
Date of change |
|
A. 18 September 2015
B. 21 September
2015 |
|
|
No. of securities held prior to change |
|
0 |
|
|
Class |
|
Ordinary shares |
|
|
Number acquired |
|
A. 100,000 ordinary shares
B. 100,000 ordinary
shares |
|
|
Number disposed |
|
N/A |
|
|
|
|
|
Value/Consideration Note: If
consideration is non-cash, provide details and estimated valuation |
|
A. $0.1635 per ordinary share
B. $0.1674 per
ordinary share |
+ |
See chapter 19 for defined terms. |
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Directors Interest Notice
|
|
|
No. of securities held after change |
|
200,000 ordinary shares |
|
|
Nature of change Example: on-market
trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back |
|
On market trade |
Part 2 Change of directors interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of notifiable interest of a director should be
disclosed in this part.
|
|
|
Detail of contract |
|
|
|
|
Nature of interest |
|
|
|
|
Name of registered holder (if issued
securities) |
|
|
|
|
Date of change |
|
|
|
|
No. and class of securities to which interest related prior to change
Note: Details are only required for a contract in relation to which the interest has changed |
|
|
|
|
Interest acquired |
|
|
|
|
Interest disposed |
|
|
+ |
See chapter 19 for defined terms. |
|
|
|
Appendix 3Y Page 2 |
|
01/01/2011 |
Appendix 3Y
Change of Directors Interest Notice
|
|
|
Value/Consideration Note: If
consideration is non-cash, provide details and an estimated valuation |
|
|
|
|
Interest after change |
|
|
Part 3 +Closed period
|
|
|
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? |
|
|
If so, was prior written clearance provided to allow the trade to proceed during this period? |
|
|
If prior written clearance was provided, on what date was this provided? |
|
|
+ |
See chapter 19 for defined terms. |
01/01/2011 Appendix 3Y Page 3
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Apr 2024 to May 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From May 2023 to May 2024